Peroxisome proliferators-activated receptor gamma polymorphisms and colorectal cancer risk
| Autor: | Kang-lian Tan, Xiao-hua Fan, Xue-Min Liang, Linchong Yu, Li Zhang, Lisi Jian |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Colorectal cancer lcsh:RC254-282 Polymorphism Single Nucleotide polymorphism 03 medical and health sciences 0302 clinical medicine Meta-Analysis as Topic Risk Factors Internal medicine Biomarkers Tumor medicine Humans Genetic Predisposition to Disease Radiology Nuclear Medicine and imaging Receptor Pro12ala polymorphism Peroxisome proliferator business.industry General Medicine Odds ratio lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognosis medicine.disease Confidence interval meta-analysis PPAR gamma 030104 developmental biology Case-Control Studies 030220 oncology & carcinogenesis Meta-analysis peroxisome proliferators-activated receptor gamma Colorectal Neoplasms business |
| Zdroj: | Journal of Cancer Research and Therapeutics, Vol 14, Iss 9, Pp 306-310 (2018) |
| ISSN: | 0973-1482 |
| Popis: | Aims: Several studies evaluated the association between peroxisome proliferators-activated receptor gamma (PPARγ) Pro12Ala (rs1801282), and His477His (rs3856806) polymorphisms and the risk of colorectal cancer (CRC). However, the results were not stable. Materials and Methods: We searched databases containing PubMed and EMBASE. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. Results: A significantly decreased CRC risk was found for PPARγ Pro12Ala polymorphism (OR = 0.88, 95% CI 0.83–0.94, P < 0.0001). In the subgroup analysis by race, a significantly decreased risk was found in the Caucasian population (OR = 0.89, 95% CI 0.83–0.95, P = 0.0003) but not in Asian population (OR = 0.76, 95% CI 0.57–1.02, P = 0.07). In the subgroup analysis by CRC location, significantly decreased risks were found in rectal cancer (OR = 0.88, 95% CI 0.77–1.00, P = 0.05) and colon cancer (OR = 0.82, 95% CI 0.73–0.92, P = 0.0008). In addition, a significantly decreased CRC risk was also detected for PPARγ His477His polymorphism (OR = 0.66, 95% CI 0.44–1.00, P = 0.05). In the subgroup analysis by race, a significantly decreased risk was found in the Caucasian population (OR = 0.43, 95% CI 0.26–0.69, P = 0.0006) but not in Asian population (OR = 0.95, 95% CI 0.73–1.25, P = 0.72). Conclusions: PPARγ Pro12Ala and His477His polymorphisms might be associated with susceptibility of CRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |